In a 71-year-old patient taking venlafaxine (Effexor) 225 mg and amlodipine who presents with severe left upper abdominal pain, hypertension, tremor of the upper and lower extremities, diaphoresis, mild agitation, and has a normal CT scan and normal laboratory studies, what is the most likely diagnosis?

Serotonin Syndrome Secondary to Venlafaxine

This patient is most likely experiencing serotonin syndrome caused by venlafaxine (Effexor) 225 mg, which is a high dose in an elderly patient and can cause this life-threatening condition even without drug interactions.

Clinical Reasoning

The constellation of symptoms—severe abdominal pain, hypertension, tremors in all extremities, diaphoresis, and agitation—strongly suggests serotonin syndrome, particularly in the context of high-dose venlafaxine therapy in a 71-year-old patient.

Key Diagnostic Features Present:

• Autonomic instability: Hypertension, diaphoresis
• Neuromuscular hyperactivity: Tremors in upper and lower extremities
• Mental status changes: Agitation
• Gastrointestinal symptoms: Severe left upper abdominal pain (can occur with serotonin syndrome)

The FDA label for Effexor explicitly warns that venlafaxine can cause serotonin syndrome, with clinical pictures including these exact symptoms 1. The drug label specifically notes that elderly patients may be at greater risk for adverse events with SNRIs like venlafaxine 1.

Why This Diagnosis Fits:

Age-related vulnerability: Research demonstrates that older adults (≥60 years) treated with venlafaxine at doses ≥225 mg/day experience significantly higher dose-corrected concentrations—by 33-59% compared to younger patients 2, 3. This patient is on exactly 225 mg, placing them in the high-risk category.

Cardiovascular effects: Venlafaxine is associated with increased blood pressure and heart rate 1. The FDA label documents mean increases in heart rate of 3-5 beats per minute and QTc prolongation in clinical trials 1. This patient's hypertension is consistent with serotonin syndrome's autonomic instability, though venlafaxine itself can cause sustained hypertension.

Case precedent: A published case report describes a patient on venlafaxine who developed serotonin syndrome with confusion, agitation, diaphoresis, and hyperkinesia, progressing to severe rhabdomyolysis and acute renal failure 4. While this patient had Parkinson's disease, it demonstrates venlafaxine's capacity to cause severe serotonin syndrome.

Critical Differential Considerations:

The normal CT scan and laboratory work help exclude:

• Acute abdominal pathology (pancreatitis, perforation, ischemia)
• Metabolic derangements initially

However, you must immediately check:

• Creatine kinase (CK) - to assess for rhabdomyolysis, which can complicate serotonin syndrome 4
• Serum sodium - venlafaxine can cause severe hyponatremia (SIADH), especially in elderly patients, with symptoms including confusion, weakness, and seizures 1
• Core temperature - fever is a key feature of moderate-to-severe serotonin syndrome
• Reflexes - hyperreflexia and clonus are diagnostic features

Alternative Diagnoses to Consider:

Venlafaxine withdrawal is unlikely given the patient is currently on medication, though abrupt dose changes can cause symptoms. Withdrawal typically presents with dizziness, nausea, and "shock-like" sensations 1, not the hyperadrenergic state seen here.

Hypertensive emergency from venlafaxine alone could explain some symptoms, but wouldn't account for the tremors and severe abdominal pain in this pattern.

Immediate Management Approach:

1. Discontinue venlafaxine immediately - this is the cornerstone of treatment
2. Supportive care: IV fluids, benzodiazepines for agitation and tremors
3. Monitor for complications: Check CK, renal function, electrolytes (especially sodium), liver enzymes
4. Blood pressure control if severely elevated (but avoid beta-blockers which can worsen symptoms)
5. Consider cyproheptadine (serotonin antagonist) if moderate-to-severe serotonin syndrome confirmed

Critical Pitfall:

Do not attribute all symptoms to "anxiety" or "depression" in a patient on high-dose venlafaxine. The FDA label explicitly warns about cardiovascular risks, seizures, and serious adverse events with venlafaxine, particularly noting that elderly patients require careful monitoring 1. The 225 mg dose places this patient at the threshold where adverse effects significantly increase 2.

The normal initial labs don't rule out serotonin syndrome—this is a clinical diagnosis based on symptoms in the context of serotonergic medication use. The Hunter Serotonin Toxicity Criteria would be met if clonus (spontaneous, inducible, or ocular) or hyperreflexia is present on examination.